HRP20040532B1 - Farmaceutski nanopartikularni pripravak antagonista receptora tahikinina - Google Patents

Farmaceutski nanopartikularni pripravak antagonista receptora tahikinina

Info

Publication number
HRP20040532B1
HRP20040532B1 HRP20040532AA HRP20040532A HRP20040532B1 HR P20040532 B1 HRP20040532 B1 HR P20040532B1 HR P20040532A A HRP20040532A A HR P20040532AA HR P20040532 A HRP20040532 A HR P20040532A HR P20040532 B1 HRP20040532 B1 HR P20040532B1
Authority
HR
Croatia
Prior art keywords
natagonist
nanoparticulate composition
tachykinin receptor
pharmaceutical
phenyl
Prior art date
Application number
HRP20040532AA
Other languages
English (en)
Inventor
Bosch William
Liversidge Elaine
Shelukar D. Suhas
Thompson Karen
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23331619&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20040532(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of HRP20040532A2 publication Critical patent/HRP20040532A2/hr
Publication of HRP20040532B1 publication Critical patent/HRP20040532B1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Nanopartikularni pripravak, naznačen time, da sadr·i spoj 2-(R)-(1-(R)-(3,5-bis(trifluorometil)fenil)etoksi)-3-(S)-(4-fluoro)fenil-4-(3-(5-okso-1H,4H-1,2,4-triazolo)metilmorfolin, ili njegovu farmaceutski prihvatljivu sol, spoj koji na svojoj povr®ini ima apsorbiran barem jedan povr®inski stablilizator u količini dovoljnoj da odr·i efektivnu prosječnu veličinu čestica manjom od oko 1000 nm. Patent sadr·i jo® 14 patentnih zahtjeva.
HRP20040532AA 2001-12-10 2004-06-09 Farmaceutski nanopartikularni pripravak antagonista receptora tahikinina HRP20040532B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34004001P 2001-12-10 2001-12-10
PCT/US2002/041655 WO2003049718A1 (en) 2001-12-10 2002-12-09 Pharmaceutical nanoparticulate composition of a tachykinin receptor antagonist

Publications (2)

Publication Number Publication Date
HRP20040532A2 HRP20040532A2 (en) 2004-10-31
HRP20040532B1 true HRP20040532B1 (hr) 2012-09-30

Family

ID=23331619

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20040532AA HRP20040532B1 (hr) 2001-12-10 2004-06-09 Farmaceutski nanopartikularni pripravak antagonista receptora tahikinina

Country Status (39)

Country Link
US (1) US8258132B2 (hr)
EP (1) EP1455756B2 (hr)
JP (1) JP4532114B2 (hr)
KR (1) KR20040063991A (hr)
CN (1) CN100352443C (hr)
AR (1) AR037713A1 (hr)
AT (1) ATE400254T1 (hr)
AU (1) AU2002360824B8 (hr)
BR (1) BRPI0214786B8 (hr)
CA (1) CA2469315C (hr)
CO (1) CO5590887A2 (hr)
CY (1) CY1108354T1 (hr)
DE (1) DE60227556D1 (hr)
DK (1) DK1455756T4 (hr)
DO (1) DOP2002000542A (hr)
EA (1) EA007332B1 (hr)
EC (1) ECSP045144A (hr)
ES (1) ES2307820T5 (hr)
GE (1) GEP20063875B (hr)
HK (1) HK1078017A1 (hr)
HR (1) HRP20040532B1 (hr)
HU (1) HU230736B1 (hr)
IL (3) IL162296A0 (hr)
IS (1) IS2991B (hr)
JO (1) JO3060B1 (hr)
ME (1) ME00450B (hr)
MX (1) MXPA04005563A (hr)
MY (1) MY155911A (hr)
NO (1) NO336943B1 (hr)
NZ (1) NZ534009A (hr)
PE (1) PE20030641A1 (hr)
PL (1) PL211243B6 (hr)
PT (1) PT1455756E (hr)
RS (1) RS52280B (hr)
SI (1) SI1455756T2 (hr)
TW (1) TWI249403B (hr)
UA (1) UA76810C2 (hr)
WO (1) WO2003049718A1 (hr)
ZA (1) ZA200404012B (hr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100356871C (zh) * 2002-02-22 2007-12-26 味之素株式会社 氨基酸粉末及其制备方法
AR045142A1 (es) * 2003-07-30 2005-10-19 Novartis Ag Composicion veterinaria masticable ductil de buen sabor
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
EP1853234A2 (en) * 2005-02-15 2007-11-14 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
WO2007016582A2 (en) * 2005-07-29 2007-02-08 Dr. Reddy's Laboratories Ltd. Amorphous aprepitant coprecipitates
US8022054B2 (en) 2005-11-28 2011-09-20 Marinus Pharmaceuticals Liquid ganaxolone formulations and methods for the making and use thereof
US9227958B2 (en) 2006-02-03 2016-01-05 Glenmark Pharmaceuticals Limited Amorphous and crystalline forms of aprepitant and processes for the preparation thereof
EP2034952A4 (en) * 2006-06-16 2011-08-17 Reddys Lab Ltd Dr APREPITANT COMPOSITIONS
WO2008026216A2 (en) * 2006-08-28 2008-03-06 Hetero Drugs Limited Process for purification of aprepitant
AU2007325628A1 (en) * 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
EP1970057A1 (en) * 2007-03-13 2008-09-17 Sandoz AG Process for the preparation of stable pharmaceutical compositions of 2-(R) - (1-(R)-(3, 5- bis (trifluoromethyl) phenyl) ethoxy)-3-(S)-(4-fluoro) phenyl-4-(3-(5-oxo-1H, 4H-1, 2, 4-triazolo) methylmorpholine (aprepitant)
WO2008110534A1 (en) * 2007-03-13 2008-09-18 Sandoz Ag Pharmaceutical compositions of poorly soluble drugs
WO2009108828A2 (en) * 2008-02-27 2009-09-03 Dr. Reddy's Laboratories Ltd. Solubility-enhanced forms of aprepitant and pharmaceutical compositions thereof
WO2009116081A2 (en) * 2008-03-03 2009-09-24 Msn Laboratories Limited An improved process for the preparation of aprepitant
BRPI0823402A2 (pt) * 2008-12-30 2015-06-16 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Formulações farmacêuticas de olmesartan
MX2011012133A (es) * 2009-05-15 2011-12-06 Glaxosmithkline Llc Uso de formacion de imagen termica para control de un proceso de fabricacion.
HUP1000325A2 (en) 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Nanostructured aprepitant compositions and process for their preparation
WO2013142258A1 (en) * 2012-03-22 2013-09-26 Nanotherapeutics, Inc. Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles
AU2013280644B2 (en) 2012-06-26 2018-08-02 Jeffrey A. BACHA Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
MX2015016024A (es) 2013-06-20 2016-04-04 Glenmark Pharmaceuticals Sa Formulacion en nanoparticulas que comprende un antagonista para trpa1.
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
CN104367551B (zh) * 2013-08-15 2017-06-13 上海星泰医药科技有限公司 一种阿瑞匹坦复合物及其制备方法
JP2016532660A (ja) * 2013-10-08 2016-10-20 イノファーマ インク アプレピタント経口液体製剤
EP2893919B1 (en) 2014-01-09 2017-07-12 Sanofi Formulation of aprepitant with enhanced solubility
DE102014004512A1 (de) * 2014-03-28 2015-10-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin Anorganisch-organische Hybridverbindung
US20170135991A1 (en) 2014-08-01 2017-05-18 Glenmark Pharmaceuticals S.A. NANOPARTICULATE FORMULATION COMPRISING A mPGES-1 INHIBITOR
KR101492572B1 (ko) 2015-01-14 2015-02-11 주식회사 대웅제약 신규 약학 조성물
KR20180082457A (ko) 2015-10-16 2018-07-18 마리누스 파마슈티컬스 인코포레이티드 나노입자들을 포함하는 주사용 뉴로스테로이드 제제들
GR1009002B (el) * 2016-03-22 2017-03-31 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα περιεχον εναν αντιεμετικο παραγοντα και μεθοδος για την παρασκευη αυτου
WO2018031748A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
GR1009209B (el) * 2016-11-17 2018-02-05 Φαρματεν Αβεε Φαρμακευτικο σκευασμα περιεχον εναν αντιεμετικο παραγοντα και μεθοδος για την παρασκευη αυτου
CN106377517A (zh) * 2016-11-25 2017-02-08 遵义医学院 银杏内酯‑pvp纳米粒及其制备方法
CN107260705A (zh) * 2017-06-08 2017-10-20 武汉励合生物医药科技有限公司 一种阿瑞匹坦纳米胶囊的制备方法
EP3658123A4 (en) 2017-07-24 2021-04-28 Acryspharm LLC PHARMACEUTICAL COMPOSITIONS WITH HIGH ACTIVE INGREDIENT LOAD
JP2019073445A (ja) * 2017-10-12 2019-05-16 日本化薬株式会社 アプレピタントを有効成分とする医薬組成物
CN108066745A (zh) * 2017-12-26 2018-05-25 兆科药业（广州）有限公司 一种环孢素眼凝胶的处理工艺
US20210213024A1 (en) 2018-02-20 2021-07-15 Ftf Pharma Private Ltd Liquid compositions of aprepitant
WO2019191391A1 (en) * 2018-03-28 2019-10-03 The Regents Of The University Of Colorado, A Body Corporate Treatment and prevention of alpha herpes virus infection
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
CN110478316A (zh) * 2019-02-27 2019-11-22 江西中医药大学 一种阿瑞吡坦纳米结晶混悬剂及其制备方法和应用
MX2022001553A (es) 2019-08-05 2022-04-18 Marinus Pharmaceuticals Inc Ganaxolona para su uso en el tratamiento del estado epileptico.
WO2021113834A1 (en) 2019-12-06 2021-06-10 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
EP3915546A1 (de) 2020-05-25 2021-12-01 Leon-Nanodrugs GmbH Verwendung von säure als lösungsmittel für präzipitationen
CN116077462A (zh) * 2022-12-01 2023-05-09 北京诺康达医药科技股份有限公司 阿瑞匹坦微丸及其制备方法和包含它的制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499299A2 (en) * 1991-01-25 1992-08-19 NanoSystems L.L.C. Surface modified drug nanoparticles
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096742A (en) 1990-01-09 1992-03-17 Hoechst Celanese Corporation High temperature, high humidity stabilization process for optical information storage media containing polycarbonate substrates
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6048859A (en) † 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
AU714542B2 (en) * 1996-06-26 2000-01-06 Warner-Lambert Company Use of a tachykinin antagonist for the manufacture of a medicament for the treatment of emesis
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
ZA985765B (en) † 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.
GB9813025D0 (en) 1998-06-16 1998-08-12 Merck Sharp & Dohme Chemical synthesis
AU5624599A (en) † 1998-08-25 2000-03-14 Lothar Farber Pharmaceutical uses
US5997905A (en) 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
WO2000076948A1 (en) 1999-06-11 2000-12-21 Merck & Co., Inc. Process for the synthesis of 1-(3,5-bis(trifluoromethyl)-phenyl)ethan-1-one
US6255545B1 (en) 1999-06-11 2001-07-03 Merck & Co., Inc. Process for the synthesis of 3,5-bis(trifluoromethyl)-bromobenzene
US20070179367A1 (en) * 2000-05-02 2007-08-02 Ruchti Timothy L Method and Apparatus for Noninvasively Estimating a Property of an Animal Body Analyte from Spectral Data
US7801591B1 (en) * 2000-05-30 2010-09-21 Vladimir Shusterman Digital healthcare information management
AU2001266690A1 (en) 2000-06-08 2001-12-17 Merck And Co., Inc. Process for the synthesis of (2r, 2-alpha-r)-4-benzyl-2-(1-(3,5-bis(trifluoromethyl)phenyl) ethoxy)-1,4-oxazin-3-one
US6931327B2 (en) * 2003-08-01 2005-08-16 Dexcom, Inc. System and methods for processing analyte sensor data

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499299A2 (en) * 1991-01-25 1992-08-19 NanoSystems L.L.C. Surface modified drug nanoparticles
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists

Also Published As

Publication number Publication date
BRPI0214786B1 (pt) 2018-11-27
JP2005516003A (ja) 2005-06-02
HRP20040532A2 (en) 2004-10-31
GEP20063875B (en) 2006-07-10
HU230736B1 (hu) 2018-01-29
WO2003049718A1 (en) 2003-06-19
ES2307820T5 (es) 2016-01-13
CN1617712A (zh) 2005-05-18
BR0214786A (pt) 2004-11-09
HK1078017A1 (en) 2006-03-03
PL211243B1 (pl) 2012-04-30
IL162296A0 (en) 2005-11-20
ZA200404012B (en) 2005-10-26
AU2002360824A1 (en) 2003-06-23
US20040214746A1 (en) 2004-10-28
IL201658A0 (en) 2011-08-01
EP1455756B1 (en) 2008-07-09
ECSP045144A (es) 2004-07-23
JP4532114B2 (ja) 2010-08-25
PL211243B6 (pl) 2023-01-23
MXPA04005563A (es) 2004-12-06
CY1108354T1 (el) 2012-05-23
ATE400254T1 (de) 2008-07-15
CN100352443C (zh) 2007-12-05
SI1455756T2 (sl) 2016-01-29
IL162296A (en) 2013-11-28
CA2469315C (en) 2008-12-02
IS2991B (is) 2017-12-15
AU2002360824B2 (en) 2008-05-08
DOP2002000542A (es) 2003-07-15
US8258132B2 (en) 2012-09-04
HUP0402596A2 (hu) 2005-03-29
EA200400794A1 (ru) 2004-10-28
HUP0402596A3 (en) 2011-05-30
PT1455756E (pt) 2008-10-16
IS7276A (is) 2004-05-21
JO3060B1 (ar) 2017-03-15
TW200301125A (en) 2003-07-01
BRPI0214786B8 (pt) 2021-05-25
DE60227556D1 (de) 2008-08-21
PL369887A1 (en) 2005-05-02
RS50404A (en) 2007-04-10
NZ534009A (en) 2006-03-31
NO20042905L (no) 2004-09-10
ME00450B (me) 2011-10-10
DK1455756T4 (en) 2016-01-04
CO5590887A2 (es) 2005-12-30
NO336943B1 (no) 2015-11-30
CA2469315A1 (en) 2003-06-19
EP1455756B2 (en) 2015-09-23
PE20030641A1 (es) 2003-07-23
AR037713A1 (es) 2004-12-01
DK1455756T3 (da) 2008-11-17
AU2002360824B8 (en) 2008-05-22
ES2307820T3 (es) 2008-12-01
UA76810C2 (uk) 2006-09-15
EP1455756A1 (en) 2004-09-15
RS52280B (en) 2012-10-31
KR20040063991A (ko) 2004-07-15
TWI249403B (en) 2006-02-21
SI1455756T1 (sl) 2008-12-31
MY155911A (en) 2015-12-15
EA007332B1 (ru) 2006-08-25

Similar Documents

Publication Publication Date Title
HRP20040532B1 (hr) Farmaceutski nanopartikularni pripravak antagonista receptora tahikinina
ES2528425T3 (es) Herbicidas selectivos a base de arilsulfonilaminocarboniltriazolinonas
CO5540327A2 (es) Composicion desecante
CA2105114A1 (en) Monohydrate of 5-(2-(4-(1,2 Benzisothiazol-3-Yl)-1- Piperazinyl)-Ethyl)-6-Chloro-1,3-Dihydro-2H-Indol-2-One Hydrochloride
RU97118224A (ru) Соединения и композиции для доставки активных агентов
EA200601145A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов
IS2617B (is) Fjölbrigðaform af kínínhröðunar mótlyfinu 2-(R)-(1-(R)-(3,5-bis(tríflúormetýl)fenýl)etoxý)-3-(S)-(4-flúor)fenýl-4-(3-(5-oxó-1H,4H-1,2,4-tríasóló)metýlmorfólíni
DK1330458T3 (da) N-(1,2,4-triazoloazinyl)thiophensulfonamidforbindelser som herbicider
DE60310936D1 (de) Riechstoffzusammensetzung
AR048948A1 (es) Una composicion farmaceutica antimicobacteriana
IS6679A (is) Ný form (R)-N-[5-metýl-8-(4-metýlpíperasín-1-ýl)-1,2,3,4-tetrahýdró-2-naftýl]-4-morfólínóbensamíðs
DE60130753D1 (de) Stabilisierung fester herbizider zusammensetzungen, die flazasulfuron enthalten
JP2001354766A5 (hr)
ES2166168T3 (es) Composiciones detergentes que contienen granulos tensioactivos no ionicos.
DE602004021704D1 (de) Wirksubstanzkombination mit einer verbindung mit npy rezeptor-affinität und einer verbindung mit 5-ht6 rezeptor-affinität
BRPI0206922B8 (pt) composto de fragrância, composição de fragrância contendo o mesmo, e método para preparação de um composto de fragrância
AU2001271418A1 (en) 2-(3,5-disubstituted-4-pyridyl)-4-(thienyl, thiazolyl or arylphenyl)-1,3-oxazoline compounds
BR9807801A (pt) Embalagem
DE60110233D1 (de) Neue n-(2-phenyl-3-aminopropyl)naphtamide
ITMI20010375V0 (it) Meccanismo d'avanzamento di una molatrice a smusso per bordi rettilinei ondulati.
AR045724A1 (es) Composicion farmaceutica orodispersable de un compuesto antitrombotico
RS52014B (sr) Nova so benzoilgvanidina
WO2002057248A3 (en) Inhibitors of cruzipain and other cysteine proteases
ECSP972089A (es) Sal mesilato trihidrato de 5-[2-[4(1,2-benzoisotiazol-3-il]-1-piperazinil)etil]-6-cloro- 1,3- dihidro- 2h- inddol - 2 - ona
FR2846005B1 (fr) Composition pour milieu biologique comprenant de l'erythorbate de sodium

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: MERCK SHARP & DOHME CORP., US

B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: SCHERING CORPORATION, US

Owner name: MERCK SHARP & DOHME CORP., US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20181204

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20191203

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20201203

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20211208

Year of fee payment: 20

PPPP Transfer of rights

Owner name: MERCK SHARP & DOHME LLC, US

PB20 Patent expired after termination of 20 years

Effective date: 20221209